COMMUNIQUÉS West-GlobeNewswire

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
02/12/2025
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in [...]
Ventyx Provides Clinical and Corporate Updates
02/12/2025
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD [...]
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
02/12/2025
The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare providers to act quickly and prevent severe complications and onward transmission. Detects and differentiates between three [...]
Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion
02/12/2025
Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros [...]
Tecan expands robotic workcell offering with acquisition of Wako Automation assets
02/12/2025
Männedorf, Switzerland, December 2, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced the acquisition of Wako Automation assets, including the flagship Director™ scheduling software and select hardware [...]
Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million
02/12/2025
COPENHAGEN, Denmark, December 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months. This [...]
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
02/12/2025
EO2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastoma Data presented at 2025 SNO conference by lead investigator Paris, France – 2 DECEMBER 2025 (08:30 CET) [...]
CARBIOS et Wankai New Materials signent l’accord définitif constitutif d’un partenariat stratégique pour déployer à très grande échelle la technologie de biorecyclage du PET de CARBIOS en Asie
02/12/2025
Clermont-Ferrand (France), 2 décembre 2025 (08h45 CET). Conformément à l’engagement signé le 6 novembre 2025 1 , CARBIOS (Euronext Growth Paris : ALCRB) et Wankai New Materials (« Wankai »), une filiale cotée 2 du [...]
CARBIOS and Wankai New Materials sign the definitive agreement establishing a strategic partnership to the large-scale deployment of CARBIOS’s PET biorecycling technology in Asia
02/12/2025
Clermont-Ferrand (France), 2 December 2025 (8:45 AM CET). In line with the commitment signed on November 6, 2025 1 , CARBIOS (Euronext Growth Paris: ALCRB) and Wankai New Materials (« Wankai »), a listed subsidiary 2 of [...]
Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease
02/12/2025
Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation [...]
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
02/12/2025
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
eDrugstore Partners with Groupon for Exclusive Black Friday and Cyber Monday Deals
02/12/2025
SCOTTSDALE, Ariz., Dec. 02, 2025 (GLOBE NEWSWIRE) -- eDrugstore, the parent company of eDrugstore.com, has partnered with Groupon to offer up to 95% off select men’s health products and telehealth services during Black [...]
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
01/12/2025
Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal [...]
Regional Health Properties Announces Series B Preferred Stock Repurchase Program
01/12/2025
ATLANTA, GA, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB:RHEPZ), today announced that its Board [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/12/2025
CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/12/2025
CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly- [...]
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01/12/2025
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, [...]
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
01/12/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN [...]
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
01/12/2025
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been [...]

Pages